Equinox Medical (Australia) is proud to announce a new partnership with ABL Diagnostics S.A Diagnostics (France)

Partnership Announcement
Equinox Medical (Australia) is proud to announce a new partnership with ABL Diagnostics S.A Diagnostics (France), a global innovator in advanced sequencing-based diagnostic technologies.

This collaboration marks a significant step in bringing Next-Generation Sequencing (NGS) and Targeted Genotyping solutions to clinical laboratories across Australia. ABL Diagnostics’ proprietary NGS assays and software platforms are designed to deliver the ability to provide highly specific and precise identification of relevant genomic variations and associated drug sensitivity information in patients affected by infectious diseases, empowering clinicians to make important decisions on the best therapy to provide to their patients.

This partnership will allow us to:
🧬 Expand access to cutting-edge sequencing tools for Australian molecular pathology labs
🧪 Support high-throughput and high-sensitivity diagnostics using ABL’s CE-IVD certified platforms
🌍 Strengthen local diagnostics capabilities in public health, hospital, and research settings

Together, Equinox and ABL Diagnostics are committed to advancing the future of sequencing in clinical diagnostics.